EZH2 and myeloid neoplasm: For myeloid malignancies, the most prevalent mutations in epigenetic regulators are in TET2, isocitrate dehydrogenase 1 and 2 (IDH1, IDH2), additional sex combs-like 1 (ASXL1), enhancer of zeste homolog 2 (EZH2), and DNA methyltransferase 3A (DNMT3A) [111,112].